Results 131 to 140 of about 108,288 (261)

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

open access: yesBritish Journal of Haematology, EarlyView.
Summary Single‐arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B‐cell lymphomas but with significant toxicities and at exceptionally high costs. The objective of this study was to evaluate the real‐world health outcomes of aggressive B‐cell lymphoma patients treated with publicly funded ...
Pierre J. A. Villeneuve   +17 more
wiley   +1 more source

Diffuse Large B-Cell Lymphoma Arising in Postpneumonectomy Cavities: Report of Two Cases and Literature Review. [PDF]

open access: yesCase Rep Med
Capdevila P   +9 more
europepmc   +1 more source

Response‐adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort

open access: yesBritish Journal of Haematology, EarlyView.
Summary Secondary central nervous system lymphoma (SCNSL) remains a rare but challenging manifestation of aggressive lymphomas, with limited prospective data to guide treatment decisions in the modern therapeutic era. We conducted a multicentre retrospective cohort study of 105 consecutively treated adult patients diagnosed with SCNSL between 2016 and ...
Farina Eigendorff   +10 more
wiley   +1 more source

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study

open access: yesBritish Journal of Haematology, EarlyView.
Real‐world nationwide data in B‐cell malignancies reveal a markedly increased 1‐year incidence of hospitalized atrial fibrillation with ibrutinib compared with second‐generation Bruton's tyrosine kinase inhibitors and venetoclax, arguing for closer cardiac surveillance.
Yoann Zelmat   +5 more
wiley   +1 more source

Effects of chronic lymphocytic leukaemia (CLL)‐directed therapy on diffuse large B‐cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

open access: yesBritish Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) type Richter transformation (DLBCL‐RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL‐RT with or without previous CLL‐directed therapy compared to dnDLBCL between 2002 and 2022.
Andreas Katsimigas   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy